Horst Urbach
Teaching Neuroimages: Dynamic Digital Subtraction Myelography Discloses a Ventral CSF Leak in a Patient with Upper Limb Amyotrophy.
Lützen N, Zeitlberger A, Beck J, Urbach H. Teaching Neuroimages: Dynamic Digital Subtraction Myelography Discloses a Ventral CSF Leak in a Patient with Upper Limb Amyotrophy. Clin Neuroradiol 2022
05.09.2022Teaching Neuroimages: Dynamic Digital Subtraction Myelography Discloses a Ventral CSF Leak in a Patient with Upper Limb Amyotrophy.
05.09.2022Clin Neuroradiol 2022
Lützen Niklas, Zeitlberger Anna, Beck Jürgen, Urbach Horst
Patient radiation exposure from intraoperative computed tomography in spinal surgery.
Klingler J, Naseri Y, Reinacher P, Hoedlmoser H, Urbach H, Hohenhaus M. Patient radiation exposure from intraoperative computed tomography in spinal surgery. Spine J 2022; 22:1576-1578.
26.03.2022Patient radiation exposure from intraoperative computed tomography in spinal surgery.
26.03.2022Spine J 2022; 22:1576-1578
Klingler Jan-Helge, Naseri Yashar, Reinacher Peter C, Hoedlmoser Herbert, Urbach Horst, Hohenhaus Marc
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678-688.
14.02.2019Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
14.02.2019Lancet 2019; 393:678-688
Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N, Proescholdt M, Steinbach J, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018; 20:975-985.
18.06.2018Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
18.06.2018Neuro Oncol 2018; 20:975-985
Schäfer Niklas, Proescholdt Martin, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Grauer Oliver, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Grau Stefan, Hänel Mathias, Schnell Oliver, Krex Dietmar, Vajkoczy Peter, Tabatabai Ghazaleh, Mack Frederic, Schaub Christina, Tzaridis Theophilos, Nießen Michael, Kebir Sied, Leutgeb Barbara, Urbach Horst, Belka Claus, Stummer Walter, Glas Martin, Herrlinger Ulrich
Histopathology of 3 Tesla MRI-negative extratemporal focal epilepsies.
Kogias E, Altenmüller D, Klingler J, Schmeiser B, Urbach H, Doostkam S. Histopathology of 3 Tesla MRI-negative extratemporal focal epilepsies. J Clin Neurosci 2018; 50:232-236.
01.04.2018Histopathology of 3 Tesla MRI-negative extratemporal focal epilepsies.
01.04.2018J Clin Neurosci 2018; 50:232-236
Kogias Evangelos, Altenmüller Dirk-Matthias, Klingler Jan-Helge, Schmeiser Barbara, Urbach Horst, Doostkam Soroush
3 Tesla MRI-negative focal epilepsies: Presurgical evaluation, postoperative outcome and predictive factors
Kogias E, Klingler J, Urbach H, Scheiwe C, Schmeiser B, Doostkam S, Zentner J, Altenmüller D. 3 Tesla MRI-negative focal epilepsies: Presurgical evaluation, postoperative outcome and predictive factors. Clin Neurol Neurosurg 2017; 163:116-120.
31.10.20173 Tesla MRI-negative focal epilepsies: Presurgical evaluation, postoperative outcome and predictive factors
31.10.2017Clin Neurol Neurosurg 2017; 163:116-120
Kogias Evangelos, Klingler Jan-Helge, Urbach Horst, Scheiwe Christian, Schmeiser Barbara, Doostkam Soroush, Zentner Josef, Altenmüller Dirk-Matthias
Histopathology of 3 Tesla MRI-negative temporal lobe epilepsies.
Kogias E, Altenmüller D, Klingler J, Schmeiser B, Urbach H, Doostkam S. Histopathology of 3 Tesla MRI-negative temporal lobe epilepsies. J Clin Neurosci 2017; 47:273-277.
15.10.2017Histopathology of 3 Tesla MRI-negative temporal lobe epilepsies.
15.10.2017J Clin Neurosci 2017; 47:273-277
Kogias Evangelos, Altenmüller Dirk-Matthias, Klingler Jan-Helge, Schmeiser Barbara, Urbach Horst, Doostkam Soroush
Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme
Heiland D, Weyerbrock A, Urbach H, Staszewski O, Kiselev V, Kellner E, Pfeifer D, Haaker G, Demerath T, Simon-Gabriel C, Mader I. Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme. Sci Rep 2017; 7:43523.
07.03.2017Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme
07.03.2017Sci Rep 2017; 7:43523
Heiland Dieter Henrik, Weyerbrock Astrid, Urbach Horst, Staszewski Ori, Kiselev Valerij G, Kellner Elias, Pfeifer Dietmar, Haaker Gerrit, Demerath Theo, Simon-Gabriel Carl Philipp, Mader Irina
Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype?
Demerath T, Weyerbrock A, Urbach H, Egger K, Kiselev V, Mast H, Staszewski O, Reinacher P, Heiland D, Lange T, Schwarzwald R, Kellner E, Simon-Gabriel C, Mader I. Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype?. Neuroradiol J 2016; 30:36-47.
19.11.2016Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype?
19.11.2016Neuroradiol J 2016; 30:36-47
Demerath Theo, Weyerbrock Astrid, Urbach Horst, Egger Karl, Kiselev Valerij G, Mast Hansjörg, Staszewski Ori, Reinacher Peter, Heiland Dieter Henrik, Lange Thomas, Schwarzwald Ralf, Kellner Elias, Simon-Gabriel Carl Philipp, Mader Irina
Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme
Heiland D, Weyerbrock A, Urbach H, Staszewski O, Schnell O, Pfeifer D, Kiselev V, Kellner E, Demerath T, Mader I. Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme. Oncotarget 2016
23.08.2016Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme
23.08.2016Oncotarget 2016
Heiland Dieter Henrik, Weyerbrock Astrid, Urbach Horst, Staszewski Ori, Schnell Oliver, Pfeifer Dietmar, Kiselev Valerij G, Kellner Elias, Demerath Theo, Mader Irina
Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme
Heiland D, Urbach H, Vasilikos I, Schwarzwald R, Lange T, Carro M, Pfeifer D, Schlosser P, Mader I, Weyerbrock A. Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme. Sci Rep 2016; 6:29052.
28.06.2016Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme
28.06.2016Sci Rep 2016; 6:29052
Heiland Dieter Henrik, Urbach Horst, Vasilikos Ioannis, Schwarzwald Ralf, Lange Thomas, Carro Maria Stella, Pfeifer Dietmar, Schlosser Pascal, Mader Irina, Weyerbrock Astrid
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016; 34:1611-9.
14.03.2016Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
14.03.2016J Clin Oncol 2016; 34:1611-9
Herrlinger Ulrich, Kortmann Rolf-Dieter, Mehdorn Maximilian, Tüttenberg Jochen, Mayer-Steinacker Regine, Fietkau Rainer, Brehmer Stefanie, Mack Frederic, Stuplich Moritz, Kebir Sied, Kohnen Ralf, Dunkl Elmar, Leutgeb Barbara, Proescholdt Martin, Pietsch Torsten, Urbach Horst, Belka Claus, Stummer Walter, Gerlach Rüdiger, Vajkoczy Peter, Schäfer Niklas, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Maciaczyk Jaroslaw, Grau Stefan, Schnell Oliver, Hänel Mathias, Krex Dietmar, Glas Martin
Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis
Heiland D, Urbach H, Schrimpf D, Capper D, Grauvogel J, Franco P, Masalha W, Hirsch M, Staszewski O, Weyerbrock A. Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis. J Neuropathol Exp Neurol 2016; 75:358-65.
27.02.2016Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis
27.02.2016J Neuropathol Exp Neurol 2016; 75:358-65
Heiland Dieter Henrik, Urbach Horst, Schrimpf Daniel, Capper David, Grauvogel Jürgen, Franco Pamela, Masalha Waseem, Hirsch Martin, Staszewski Ori, Weyerbrock Astrid
Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases
Bilger A, Milanovic D, Lorenz H, Oehlke O, Urbach H, Schmucker M, Weyerbrock A, Nieder C, Grosu A. Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clin Neurol Neurosurg 2016; 142:81-6.
14.01.2016Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases
14.01.2016Clin Neurol Neurosurg 2016; 142:81-6
Bilger Angelika, Milanovic Dusan, Lorenz Hannah, Oehlke Oliver, Urbach Horst, Schmucker Marianne, Weyerbrock Astrid, Nieder Carsten, Grosu Anca-Ligia